Viewing Study NCT01750606


Ignite Creation Date: 2025-12-26 @ 1:19 PM
Ignite Modification Date: 2026-03-03 @ 8:18 PM
Study NCT ID: NCT01750606
Status: UNKNOWN
Last Update Posted: 2016-08-05
First Post: 2012-11-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An MRI Investigation of Soft Tissues in Total Hip Arthroplasty
Sponsor: Zimmer Biomet
Organization:

Study Overview

Official Title: An MRI Investigation of Soft Tissues in Total Hip Arthroplasty
Status: UNKNOWN
Status Verified Date: 2016-07
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MoM_MRI
Brief Summary: Retrospective study to comply with FDA's post-market surveillance order. The purpose of the study is to contact patients who have received a Biomet metal-on-metal product as their primary total hip arthroplasty device. Patients who have not been revised prior to contact will be asked to submit to a blood draw, clinical exam and MRI.
Detailed Description: This study has been designed to estimate the prevalence of soft tissue changes following primary THA surgery in patients having received one of five Biomet implant types; a MOP primary THA, an M2a 38, M2a Taper, M2a Ringloc and M2a Magnum MOM primary THA device in 308-436 total patients at four centers.

The primary objective of the study is to estimate the prevalence of soft tissue changes in unbiased MoM and MoP samples. Secondary objectives are to evaluate whether the occurrence of soft tissue changes is related to any of several potential covariates including patient and implant characteristics and time in situ.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
PS110005-28 OTHER FDA View